Radioactive Iodine-Refractory Thyroid Cancer

The FDA granted breakthrough therapy designation to cabozantinib for treatment of certain patients with thyroid cancer, according to the agent’s manufacturer.

An 18 mg starting dose of the oral tyrosine kinase inhibitor lenvatinib did not meet the noninferiority requirement compared with the approved, 24 mg starting dose for adults with radioactive iodine-refractory thyroid cancer, data show.

Adults with radioactive iodine-refractory thyroid cancer and sarcopenia who are treated with sorafenib are no more likely to experience a dose modification due to drug toxicity than a similar patient without sarcopenia, according to findings from an exploratory analysis of the DECISION trial.

CHICAGO — Redifferentiation therapy with MEK inhibitor and/or BRAF inhibitor therapy resensitized some patients with metastatic radioactive iodine-refractory thyroid cancer to radioactive iodine, according to retrospective study results presented at the Annual Meeting of the American Thyroid Association.

CHICAGO — Apatinib demonstrated encouraging clinical activity among Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer, according to results of a small phase 2 study presented at the Annual Meeting of the American Thyroid Association.